Incyte will release second-quarter earnings on July 28
The biopharmaceutical company Incyte announced that it will release its second quarter financial results for 2026 before the U.S. stock market opens on July 28, and will hold an earnings conference call and webcast at 8:00 a.m. that day. The upcoming second quarter report has attracted much market attention. The company's first-quarter performance was strong, with revenue reaching US$1.27 billion, a year-on-year increase of 20.9%, and earnings per share of US$1.81, far exceeding market expectations of US$1.38. Analysts currently expect second-quarter revenue of about $911 million and adjusted earnings per share of about $1.01. One of the highlights of this financial report is related to Opzelura cream. Incyte recently reached a settlement with the U.S. Centers for Medicare and Medicaid Services over Opzelura's Medicaid rebate rules and will recognize a non-cash one-time benefit of approximately $246 million in the second quarter, which is expected to significantly boost revenue data. There are also positive signals at the product level. The Committee for Medicinal Products for Human Use of the European Medicines Agency recently issued a positive opinion recommending the approval of Opzelura cream for adult patients with moderate atopic dermatitis. If approved by the European Commission, Opzelura will become the EU's first non-hormonal topical JAK inhibitor for moderate atopic dermatitis. Analysts are paying attention to whether the company will update Opzelura's gross-to-net assumption guidance or raise its fiscal 2026 performance forecast for the product. Institutions have also recently adjusted their ratings and target prices on Incyte. Maintaining a Neutral rating and raising the price target to $113 from $103, HC Wainwright maintained a Buy rating and raised the price target to $140.